Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02368340 · ClinicalTrials.gov registry record
A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
A clinical trial of Hermansky Pudlak Syndrome, sponsored by Vanderbilt University.
- Completed
- Registry status
- 55
- Enrollment target
- 5
- Study locations
NCT02368340: Completed study of Hermansky Pudlak Syndrome, sponsored by Vanderbilt University.
NCT02368340 is a study of Hermansky Pudlak Syndrome that has completed, run by Vanderbilt University. The registered enrollment target is 55 participants. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02368340, a study of Hermansky Pudlak Syndrome, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath and progressive decline in lung function. In HPS patients with at-risk subtypes, almost all adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation. The purpose of this study is to identify the earliest measurable pulmonary disease activity in individuals at-risk for HPS pulmonary fibrosis. The study also aims to develop biomarkers that will aid in understanding of the causes of HPS pulmonary fibrosis and facilitate more rapid conduct of therapeutic trials in HPS patients with mild pulmonary disease in the future.
Conditions Studied
Interventions
- OTHER Sample collection
- OTHER Pulmonary function test
- OTHER Chest CT
Study Locations (5)
Illinois
- Loyola University Medical Center - Maywood
Massachusetts
- Brigham and Women's Hospital, Harvard - Boston
New York
- Columbia University Medical Center - New York
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-10-15 |
What the finished NCT02368340 record still lists
NCT02368340 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 1 condition, with Hermansky Pudlak Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Sample collection is the first listed.
NCT02368340 lists 5 locations in 5 states (Illinois, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT02368340 about?
NCT02368340 is a clinical study titled "A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis". Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath and progressive decline in lung functi...
What is the current status of trial NCT02368340?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2015-03. Estimated completion is 2019-10-15.
What conditions does trial NCT02368340 study?
This clinical trial studies the following conditions: Hermansky Pudlak Syndrome.
What interventions are being tested in trial NCT02368340?
The interventions under investigation include: Sample collection (OTHER), Pulmonary function test (OTHER), Chest CT (OTHER).
Who is sponsoring clinical trial NCT02368340?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02368340 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia